![Florian Muellershausen](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Florian Muellershausen
Directeur/Membre du Conseil chez
FoRx Therapeutics AG
Profil
Florian Muellershausen currently works at Novartis Venture Funds, as Managing Director from 2017, Amphista Therapeutics Ltd., as Non-Executive Director, FoRx Therapeutics AG, as Director, and Anaveon AG, as Member-Supervisory Board from 2019.
Postes actifs de Florian Muellershausen
| Sociétés | Poste | Début |
|---|---|---|
Novartis Venture Funds
 Novartis Venture Funds Investment ManagersFinance NVF invests in companies located across North America and Europe. The firm focuses on biotechnology & biopharmaceutical and Life science sectors. It provides financing for early and later stage transactions with an investment size up to USD 30 million per company and also acts as lead or co-lead investor. The firm takes a seat on the board of directors. | Private Equity Investor | 01/10/2017 |
Anaveon AG
 Anaveon AG BiotechnologyHealth Technology Develops biologics for cancer | Directeur/Membre du Conseil | 26/02/2019 |
FoRx Therapeutics AG
 FoRx Therapeutics AG Pharmaceuticals: MajorHealth Technology Develops cancer treatment compounds | Directeur/Membre du Conseil | - |
Amphista Therapeutics Ltd.
 Amphista Therapeutics Ltd. BiotechnologyHealth Technology Develops biotechnology products | Directeur/Membre du Conseil | - |
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
4
Relations au 1er degré
4
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 4 |
|---|---|
Novartis Venture Funds
Novartis Venture Funds Investment ManagersFinance NVF invests in companies located across North America and Europe. The firm focuses on biotechnology & biopharmaceutical and Life science sectors. It provides financing for early and later stage transactions with an investment size up to USD 30 million per company and also acts as lead or co-lead investor. The firm takes a seat on the board of directors. | Finance |
Anaveon AG
Anaveon AG BiotechnologyHealth Technology Develops biologics for cancer | Health Technology |
Amphista Therapeutics Ltd.
Amphista Therapeutics Ltd. BiotechnologyHealth Technology Develops biotechnology products | Health Technology |
FoRx Therapeutics AG
FoRx Therapeutics AG Pharmaceuticals: MajorHealth Technology Develops cancer treatment compounds | Health Technology |
Choisissez Zonebourse 
